Home » Topics » BioWorld Science, Endocrine/metabolic

BioWorld Science, Endocrine/metabolic
RSS

PS-PLA1 as new therapeutic target in hyperthyroidism disorders

April 20, 2020

Shanghai Ennova Biopharmaceutical describes new SSAO inhibitors

April 16, 2020

New melanocortin MC4 receptor agonists identified at Palatin Technologies

April 14, 2020

Jnana Therapeutics describes new compounds targeting mutant mammalian proteins

April 9, 2020

Clinical trial application for ACN-00177 approved in the U.K.

April 9, 2020

Selective circadian regulation may yield new therapies

April 8, 2020

FDA clears Polaryx's IND for PLX-200 in juvenile neuronal ceroid lipofuscinosis

April 8, 2020

Crinetics reports interim data from phase II ACROBAT EDGE trial of paltusotine in acromegaly

April 7, 2020

European Commission approves Nilemdo and Nustendi

April 7, 2020

Millendo Therapeutics discontinues development of livoletide for PWS

April 7, 2020

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for May 5, 2026
Axsome’s Auvelity cleared for large Alzheimer’s agitation market
BioWorld
Axsome Therapeutics Inc. won U.S. FDA approval for Auvelity (AXS-05) to treat Alzheimer’s disease agitation, a condition that affects up to three-quarters of...
Sonire starts US study of cancer HIFU after $18M series A
BioWorld
Sonire Therapeutics Inc. initiated a U.S.-based Sunrise II study of Suizenji, its novel ultrasound-guided high-intensity focused ultrasound (HIFU) system designed...
How to Summit up? Dis-Harmoni on ivonescimab NSCLC phase III
BioWorld
Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc.,...